Food U.S. and Drug Administration. Accelerated approval letter sent to Travere Therapeutics, Inc. February 17, 2023. Accessed November 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216403Orig1s000ltr.pdf

• PubMed
Food U.S. and Drug Administration. Accelerated approval letter sent to Travere Therapeutics, Inc. February 17, 2023. Accessed November 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216403Orig1s000ltr.pdf)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, et al.; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 2023; 401:1584–1594. doi: 10.1016/S0140-6736(23)00569-X

• PubMed
Heerspink HJL, ; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 2023; 401:1584–1594. doi: 10.1016/S0140-6736(23)00569-X)| false
• Search Google Scholar
• Export Citation

Rovin BH, et al.; DUPRO Steering Committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-Year results from a randomised, active-controlled, phase 3 trial. Lancet (published online November 3, 2023). doi: 10.1016/S0140-6736(23)02302-4

• PubMed
Rovin BH, ; DUPRO Steering Committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-Year results from a randomised, active-controlled, phase 3 trial. Lancet (published online November 3, 2023). doi: 10.1016/S0140-6736(23)02302-4)| false
• Search Google Scholar
• Export Citation

Rheault MN, et al.; DUPRO Steering Committee and DUPLEX Investigators. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N Eng J Med (published online November 3, 2023). doi: 10.1056/NEJMoa2308550

• PubMed
Rheault MN, ; DUPRO Steering Committee and DUPLEX Investigators. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N Eng J Med (published online November 3, 2023). doi: 10.1056/NEJMoa2308550)| false
• Search Google Scholar
• Export Citation

Tuttle KR, et al. Study design and baseline characteristics for aldosterone synthase inhibition in CKD. Am J Nephrol (published online October 30, 2023). doi: 10.1159/000534808

• PubMed
Tuttle KR, Study design and baseline characteristics for aldosterone synthase inhibition in CKD. Am J Nephrol (published online October 30, 2023). doi: 10.1159/000534808)| false
• Search Google Scholar
• Export Citation

Heerspink HJ, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): A multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet (published online November 3, 2023). doi: 10.1016/S0140-6736(23)02230-4

• PubMed
Heerspink HJ, Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): A multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet (published online November 3, 2023). doi: 10.1016/S0140-6736(23)02230-4)| false
• Search Google Scholar
• Export Citation

Kaufman D, et al. MDR-101-MLK update: Operational immune tolerance achieved in living related HLA-matched kidney transplant recipients [Abstract]. J Am Soc Nephrol 2023; 34:B3

• PubMed
Kaufman D, MDR-101-MLK update: Operational immune tolerance achieved in living related HLA-matched kidney transplant recipients [Abstract]. J Am Soc Nephrol 2023; 34:B3)| false
• Search Google Scholar
• Export Citation

Garg AX, et al. Effect of a novel multicomponent intervention to improve patient access to kidney transplant and living kidney donation: The EnAKT LKD cluster randomized clinical trial. JAMA Intern Med (published online November 3, 2023). doi: 10.1001/jamainternmed.2023.5802

• PubMed
Garg AX, Effect of a novel multicomponent intervention to improve patient access to kidney transplant and living kidney donation: The EnAKT LKD cluster randomized clinical trial. JAMA Intern Med (published online November 3, 2023). doi: 10.1001/jamainternmed.2023.5802)| false
• Search Google Scholar
• Export Citation

Akizawa T, et al. AYAME study: Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in diabetic kidney disease (DKD) patients [Abstract]. J Am Soc Nephrol 2023; 34:B1

• PubMed
Akizawa T, AYAME study: Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in diabetic kidney disease (DKD) patients [Abstract]. J Am Soc Nephrol 2023; 34:B1)| false
• Search Google Scholar
• Export Citation

Nangaku M, et al. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: Design and baseline characteristics of the AYAME study. Nephrol Dial Transplant 2023; 38:1204–1216. doi: 10.1093/ndt/gfac242

• PubMed
Nangaku M, Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: Design and baseline characteristics of the AYAME study. Nephrol Dial Transplant 2023; 38:1204–1216. doi: 10.1093/ndt/gfac242)| false
• Search Google Scholar
• Export Citation

Rossingnol P, et al. Aldosterone Antagonist Chronic Hemodialysis Interventional Survival Trial (ALCHEMIST): Primary results [Abstract]. J Am Soc Nephrol 2023; 34:B2

• PubMed
Rossingnol P, Aldosterone Antagonist Chronic Hemodialysis Interventional Survival Trial (ALCHEMIST): Primary results [Abstract]. J Am Soc Nephrol 2023; 34:B2)| false
• Search Google Scholar
• Export Citation